Karen Carey

York

Managing Editor at BioWorld

Managing Editor at BioWorld MedTech

Analyst for Clarivate Analytics' BioWorld

Featured in: Favicon

bioworld.com Favicon

desmoinesregister.com Favicon

recordcourier.com Favicon

thehrdirector.com Favicon

minutehack.com Favicon

trainingindustry.com Favicon

trainingjournal.com Favicon

smartbrief.com Favicon

pmtoday.co.uk Favicon

corp.smartbrief.com

Articles

FDA clears Satsuma’s Atzumi for migraine

1 week ago | bioworld.com | Karen Carey

FDA clears Satsuma’s Atzumi for migraineFollowing a complete response letter last year, Satsuma Pharmaceuticals Inc. received U.S. FDA approval of dihydroergotamine nasal powder to treat acute migraine with or without aura. Branded Atzumi, it is the first product that uses Satsuma’s SMART (Simple MucoAdhesive Release Technology) platform that combines an advanced powder and device technology aimed at making delivery more simple. BioWorld Asia Regulatory Neurology/psychiatric Small molecule U.S. FDA
FDA clears Satsuma’s Atzumi for migraine

2 weeks ago | bioworld.com | Karen Carey

FDA clears Satsuma’s Atzumi for migraineFollowing a complete response letter last year, Satsuma Pharmaceuticals Inc. received U.S. FDA approval of dihydroergotamine nasal powder to treat acute migraine with or without aura. Branded Atzumi, it is the first product that uses Satsuma’s SMART (Simple MucoAdhesive Release Technology) platform that combines an advanced powder and device technology aimed at making delivery more simple.
FDA clears Satsuma’s Atzumi for migraine

2 weeks ago | bioworld.com | Karen Carey

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Filling the NIH funding gap to protect biopharma research

2 weeks ago | bioworld.com | Karen Carey

Filling the NIH funding gap to protect biopharma researchThe Trump administration’s broad slash to university research budgets raises pertinent questions over impacts to the biopharma ecosystem, specifically how a changed trajectory of early research programs will affect tomorrow’s treatments and cures. Who is going to bridge research from idea to company if grants from the U.S. NIH are no longer an option? BioWorld Analysis and data insight U.S. NIH Policy
Granite Bio emerges with $100M raised and two immunology assets

3 weeks ago | bioworld.com | Karen Carey

Home » Granite Bio emerges with $100M raised and two immunology assets BioWorld briefs for April 24, 2025. BioWorld MedTech briefs for April 23, 2025. BioWorld Asia briefs for April 22, 2025 U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an...
Spruce acquires Biomarin’s Sanfilippo drug, tralesinidase alfa

1 month ago | bioworld.com | Karen Carey

Spruce acquires Biomarin’s Sanfilippo drug, tralesinidase alfaAfter dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the rare genetic neurodegenerative disease Sanfilippo syndrome type B. If approved, the therapy, tralesinidase alfa, could bring Spruce a priority review voucher. BioWorld Clinical Deals and M&A Neurology/psychiatric Enzyme U.S.
Aiming for autoimmunity, Merida Bio launches with $121M series A

1 month ago | bioworld.com | Karen Carey

ImmuneAiming for autoimmunity, Merida Bio launches with $121M series AWhen an autoimmune disease disrupted the life of someone close to scientist Dario Gutierrez, an idea emerged for a new company called Merida Biosciences focused on removing misdirected antibodies and their negative effects using Fc biotherapeutics. BioWorld Science Financings Newco news Immune Protein Series A U.S.
Aiming for autoimmunity, Merida Bio launches with $121M series A

1 month ago | bioworld.com | Karen Carey

Home » Aiming for autoimmunity, Merida Bio launches with $121M series A BioWorld briefs for April 8, 2025. BioWorld MedTech briefs for April 7, 2025. The I148M mutation in the PNPLA3 gene, which encodes patatin-like phospholipase domain-containing protein 3, is known to confer risk of fatty liver, cirrhosis and... At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
Airna’s $155M series B advances RNA editing drug AIR-001 for AATD

1 month ago | bioworld.com | Karen Carey

Genetic/congenitalAirna’s $155M series B advances RNA editing drug AIR-001 for AATDAs it prepares to advance its lead RNA editing candidate, AIR-001, into a phase I/II trial for alpha-1 antitrypsin deficiency, Airna Corp. Inc. closed an oversubscribed $155 million series B financing less than a year after completing its series A round.
Airna’s $155M series B advances RNA editing drug AIR-001 for AATD

1 month ago | bioworld.com | Karen Carey

Airna’s $155M series B advances RNA editing drug AIR-001 for AATDAs it prepares to advance its lead RNA editing candidate, AIR-001, into a phase I/II trial for alpha-1 antitrypsin deficiency, Airna Corp. Inc. closed an oversubscribed $155 million series B financing less than a year after completing its series A round. BioWorld Financings Gastrointestinal Respiratory Series B U.S.